24 LC 54 0369

House Bill 1352

By: Representatives Glaize of the 67th, Gilliard of the 162nd, Bennett of the 94th, Clark of the 108th, Davis of the 87th, and others

A BILL TO BE ENTITLED AN ACT

- 1 To amend Article 5 of Chapter 4 of Title 26 of the Official Code of Georgia Annotated,
- 2 relating to prescription drugs, so as to provide that prescribers provide certain information
- 3 to patients or their representatives prior to prescribing Schedule II controlled substances or
- 4 opioids; to provide definitions; to provide for procedures for the delivery and recordation of
- 5 such information; to provide for exceptions; to provide for related matters; to repeal
- 6 conflicting laws; and for other purposes.

7 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

8 SECTION 1.

- 9 Article 5 of Chapter 4 of Title 26 of the Official Code of Georgia Annotated, relating to
- 10 prescription drugs, is amended by adding a new Code section to read as follows:
- 11 "<u>26-4-91.</u>
- 12 (a) As used in this Code section, the term:
- (1) 'Opioid' means any opiate, opioid, opioid analgesic, or opioid derivative.
- 14 (2) 'Prescriber' means a physician, dentist, or other person licensed, registered, or
- otherwise authorized under the laws of this state, or any other state or territory of the

24 LC 54 0369

16 United States, to prescribe a controlled substance in the course of professional practice

- in this state.
- 18 (3) 'Schedule II controlled substance' means any substance so included under Code
- Section 16-13-26 and includes all substances so defined in 21 C.F.R. Part 1308, as they
- 20 may be revised from time to time.
- 21 (b) In addition to the provision of information regarding the addictive risks of opioid use
- required pursuant to Code Section 16-13-56.1, prior to issuing a prescription for a Schedule
- 23 <u>II controlled substance or an opioid in the initial course of treatment of a patient, and again</u>
- 24 prior to issuing the third prescription of the course of treatment, a prescriber shall discuss
- with the patient, or the patient's parent or guardian if the patient is under 18 years of age
- and is not an emancipated minor, the following:
- 27 (1) Information concerning:
- 28 (A) The possibility of developing an addiction to any Schedule II controlled substance,
- 29 <u>even when taken as prescribed;</u>
- 30 (B) The possibility of developing a physical or psychological dependence on the
- 31 Schedule II controlled substance or opioid; and
- 32 (C) The risk of fatal respiratory depression if the patient takes a larger dose of the
- 33 Schedule II controlled substance or opioid than prescribed, or mixes benzodiazepines,
- 34 <u>alcohol, or any other central nervous system depressant with the Schedule II controlled</u>
- 35 <u>substance or opioid;</u>
- 36 (2) Why the prescriber believes the prescription is necessary;
- 37 (3) Alternative treatment options to the prescription that are available; and
- 38 (4) The associated risks and benefits of such alternative treatments.
- 39 (c) The prescriber shall make reasonable efforts to ascertain that the patient or the patient's
- 40 parent or guardian, as applicable, understands the information provided pursuant to
- 41 <u>subsection (b) of this Code section, and shall include a note in the patient's medical record</u>

LC 54 0369

that the prescriber has discussed such information with the patient or the patient's parent or guardian.

(d) This Code section shall not apply to prescriptions for Schedule II controlled substances or opioids for a patient who is receiving treatment for cancer, palliative care, or hospice care from a licensed hospice or who is a resident of a long-term care facility, or to any medications that are being prescribed for use in the treatment of substance abuse or opioid dependence."

49 SECTION 2.

All laws and parts of laws in conflict with this Act are repealed.